drugset / Trial / NCT00505635
Biochemotherapy With Temozolomide for Metastatic Melanoma
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to learn if treatment with Temodar (temozolomide), Velban (vinblastine), Cisplatin, Proleukin (interleukin-2), Intron-A (interferon alpha), and thalidomide can help to control melanoma that has spread to other parts of the body. The safety of this treatment will also be studied.
Timeline
- Start
- 2007-03
- Primary completion
- 2010-04
- Completion
- 2010-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 20 mg/m2 | Intravenous |
| Subject | Temozolomide | Small molecule | 250 mg/m2 | Oral |
| Subject | Thalidomide | Other / unclassified | 400 mg | Oral |
| Subject | Vinblastine | Small molecule | 1.5 mg/m2 | Intravenous |
| Subject | aldesleukin | Protein / enzyme biologic | 9e+06 iu | Intravenous |
| Subject | interferon alfa-2b | Protein / enzyme biologic | 5e+06 iu | Subcutaneous |